About CCS

Comprehensive Chromosomal Screening

CCRM Toronto is pleased to offer comprehensive chromosomal screening (CCS). CCS is performed in conjunction with IVF, and is particularly important to women 35 years of age or older whose eggs are at increased risk for chromosomal errors. An estimated 70 percent of early miscarriage is associated with a chromosomal abnormality of the fetus.

CCS testing is performed on a few cells biopsied from a day five embryo (called a blastocyst). The genetic material of the embryo isn’t altered in any way during the procedure. Blastocysts are then cryopreserved using a flash freezing method called vitrification. Embryo survival after vitrification is approximately 98 percent.

After CCS, only embryos that have the correct number of chromosomes (euploid) are selected for transfer back to your uterus.

Next-Generation Sequencing (NGS)

Next-generation sequencing is the latest technological breakthrough in pre-implantation genetic testing. NGS allows us to study all 23 pairs of chromosomes at a more comprehensive level, and with deeper resolution. CCRM’s CCS lab has rigorously validated the accuracy, reproducibility and reliability of this innovative new CCS NGS platform (VeriSeq™ by Illumina).

Who should consider CCS?

  • Women 35 years of age or older
  • Women with a history of repeated miscarriage
  • Women with a previous pregnancy involving a chromosomal abnormality
  • Women who have had multiple failed cycles

Added benefits of CCS

Waiting for CCS results and vitrifying the embryos has an added benefit: it offers some time for your body to return to a normal hormonal state after ovarian stimulation. Studies have shown that transferring embryos into a uterus that’s in a more natural hormonal state enhances the likelihood of implantation and a healthier outcome.

As the worldwide pioneer of blastocyst CCS, the CCRM network is delighted to announce over 2000 healthy babies born, and countless ongoing pregnancies.